Roche Receives EMA CHMP Recommendation For Approval Of Macular Degeneration Treatment Susvimo
Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMDPositive recommendation is based on data from the LADDER, Archway and Portal studies
Roche's new eye medicine got a thumbs-up from European health experts, meaning it could soon be available to patients who have trouble seeing. This is good news because the medicine is different—it's a tiny pump instead of regular shots in the eye.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.